- 专利标题： Treatment of fibrosis using FXR ligands
-
申请号： US16228944申请日： 2018-12-21
-
公开(公告)号： US10987362B2公开(公告)日： 2021-04-27
- 发明人: Stefano Fiorucci , Roberto Pellicciari , Mark Pruzanski
- 申请人： Intercept Pharmaceuticals, Inc.
- 申请人地址： US NY New York
- 专利权人： Intercept Pharmaceuticals, Inc.
- 当前专利权人： Intercept Pharmaceuticals, Inc.
- 当前专利权人地址： US NY New York
- 代理机构： Cooley LLP
- 代理商 Ivor R. Elrifi; Chen Chen
- 主分类号： A61K31/575
- IPC分类号： A61K31/575 ; A61P1/16 ; A61K9/00
摘要：
The present invention relates to a method for inhibiting fibrosis that occurs in an organ where the farnesoid X receptor (FXR) is expressed. This method involves the step of administering a high potency, activating ligand of FXR in an effective amount to a patient who is not suffering from a cholestatic condition. The invention also provides pharmaceutical compositions containing an effective amount of an FXR ligand and kits for dispensing the pharmaceutical compositions.
信息查询
